RxDoctor Payments Data

Afnan Tariq, MD

Interventional Cardiology · Orange, CANPI 1194146431

Payments from drug & device makers

$7,035in general payments, 2019–2025

Across 84 payments — averaging $83.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Medtronic$1K
  • Impulse Dynamics (USA) Inc.$309
  • Siemens Medical Solutions USA, Inc.$205
  • Edwards Lifesciences$203
  • Boston Scientific$185
  • plus $1K from 18 others

What the payments were for

  • Grants$661%
  • Travel & lodging$2,47635%
  • Food & beverage$4,49364%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,035 in reported general payments places this provider in the 40th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$122,969
Medicare patients
301
Services billed
1,305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban34$46,017
JardianceEmpagliflozin35$41,179
OzempicSemaglutide23$21,423
MounjaroTirzepatide19$21,206
XareltoRivaroxaban12$19,368
Ranolazine ErRanolazine17$3,882
Metoprolol Succinate114$2,051
Rosuvastatin Calcium137$1,777
Valsartan25$1,195
Losartan Potassium39$489
Ezetimibe24$416
Furosemide63$394
Diltiazem 24hr Er (Cd)Diltiazem Hcl13$371
SotalolSotalol Hcl16$371
Flecainide Acetate13$301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$23$21,20619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →